Safety and Efficacy of Ranibizumab and Luseogliflozin Combination Therapy in Patients with Diabetic Macular Edema: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.

Introduction: Diabetic macular edema (DME) threatens daily life activities such as reading and driving and reduces the patients' quality-of-life. Recently, anti-vascular endothelial growth factor (VEGF) agents have become a first-line therapy in DME. However, therapy with anti-VEGF agents has several problems: repeated invasive injections are required; medical costs are high; and a certain proportion of patients with DME are resistant to treatment with anti-VEGF agents.

Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.

We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy. A 30-year-old woman with poorly controlled type 2 diabetes mellitus visited our clinic in 2004. She had moderate pre-proliferative diabetic retinopathy OU.

Pattern visual evoked potentials in Japanese patients with multiple sclerosis without history of visual pathway involvement.

A delay of the peak latency of the pattern visual evoked cortical potentials (pVEP) is accepted as one of the paraclinical evidence for a diagnosis of multiple sclerosis (MS). The purpose of this study was to evaluate the pVEPs in Japanese patients with MS without a history of visual pathway involvement. We studied the medical records of 29 MS patients without any history of visual pathway involvement, and with visual acuity correctable to > or = 20/20.